Sakuranetin reverses vascular peribronchial and lung parenchyma remodeling in a murine model of chronic allergic pulmonary inflammation

Background and purpose: Asthma is a disease of high prevalence and morbidity that generates high costs in hospitalization and treatment. Although the airway is involved in the physiopathology of asthma, there is also evidence of the importance of vascular and lung parenchyma inflammation and remodeling, which can contribute to the functional pulmonary alterations observed in asthmatic patients. Our aim was to evaluate treatment using sakuranetin, a flavone isolated from the twigs of Baccharis retusa (Asteraceae), on vascular and lung parenchyma alterations in an experimental murine model of asthma. Methods: Male BALB/c mice were subjected to a sensitization protocol with ovalbumin for 30 days and were treated with or without sakuranetin (20 mg/kg/mice) or dexamethasone (5 mg/kg/mice); then, the lungs were collected for histopathological analysis. We evaluated extracellular matrix remodeling (collagen and elastic fibers), inflammation (eosinophils and NF-kB) and oxidative stress (8-isoprostane) in the pulmonary vessels and lung parenchyma. The thickness of the vascular wall was quantified, as well as the vascular endothelial growth factor (VEGF) levels. Results: We demonstrated that sakuranetin reduced the number of eosinophils and elastic fibers in both the pulmonary vessels and the lung parenchyma, probably due to a reduction of oxidative stress and of the transcription factor NF-kB and VEGF levels in the lung. In addition, it reduced the thickness of the pulmonary vascular wall. The treatment had no effect on the collagen fibers. In most of the parameters, the effect of sakuranetin was similar to the dexamethasone effect. Conclusions and implications: Sakuranetin had anti-inflammatory and antioxidant effects, preventing vascular and distal parenchyma changes in this experimental model of asthma.

Palavras-chave

Bronchial asthma, Sakuranetin, Remodeling, Oxidative stress, Peribronchial vessels, Lung parenchyma

URI

https://observatorio.fm.usp.br/handle/OPI/17012

Referências

Angeli P, 2008, AM J PHYSIOL-LUNG C, V294, pL1197, DOI 10.1152/ajplung.00199.2007
Arantes-Costa FM, 2008, TOXICOL PATHOL, V36, P680, DOI 10.1177/0192623308317427
Ather JL, 2011, AM J RESP CELL MOL, V44, P631, DOI 10.1165/rcmb.2010-0106OC
Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029
Chetta Alfredo, 2007, Inflammation & Allergy Drug Targets, V6, P41, DOI 10.2174/187152807780077273
Correa-Costa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014298
Das M, 2003, INFLAMM RES, V52, P101, DOI 10.1007/s000110300021
Detoraki A, 2010, ALLERGY, V65, P946, DOI 10.1111/j.1398-9995.2010.02372.x
Dolhnikoff M, 1998, AM J RESP CRIT CARE, V158, P1607
Dornas W. C., 2007, Revista de Ciencias Farmaceuticas Basica e Aplicada, V28, P241
Funaguchi N, 2007, CLIN EXP PHARMACOL P, V34, P766, DOI 10.1111/j.1440-1681.2007.04636.x
Gomulka Krzysztof, 2009, Pneumonol Alergol Pol, V77, P549
Grecco SD, 2012, BIOCHEM SYST ECOL, V42, P21, DOI 10.1016/j.bse.2011.12.014
Hamid Q, 2012, RESPIRATION, V84, P4, DOI 10.1159/000339550
Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P167
Hirano T, 2004, INT ARCH ALLERGY IMM, V134, P135, DOI 10.1159/000078498
Jung WK, 2009, FOOD CHEM TOXICOL, V47, P293, DOI 10.1016/j.fct.2008.11.012
Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006
Kimata M, 2000, CLIN EXP ALLERGY, V30, P501, DOI 10.1046/j.1365-2222.2000.00768.x
Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403
Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505
Lago JHG, 2014, MOLECULES, V19, P3570, DOI 10.3390/molecules19033570
Lancas T, 2006, J APPL PHYSIOL, V100, P1610, DOI 10.1152/japplphysiol.00828.2005
Lee Chun Geun, 2011, Proc Am Thorac Soc, V8, P512, DOI 10.1513/pats.201102-018MW
Li X, 1997, AM J RESP CRIT CARE, V156, P229
Luna LG., 1986, AFIP MANUAL HISTOLOG
Mahmoud YI, 2012, MICRON, V43, P1050, DOI 10.1016/j.micron.2012.04.014
Mauad T., 2000, J PNEUMOL, V26, P91
Middleton E, 2000, PHARMACOL REV, V52, P673
Mojzis J, 2008, PHARMACOL RES, V57, P259, DOI 10.1016/j.phrs.2008.02.005
OHRUI T, 1992, AM REV RESPIR DIS, V146, P1501
Prado CM, 2006, AM J RESP CELL MOL, V35, P457, DOI 10.1165/rcmb.2005-0391OC
Prado CM, 2011, EXP LUNG RES, V37, P259, DOI 10.3109/01902148.2010.538289
RighettI RF, 2014, RESP PHYSIOL NEUROBI, V192, P134, DOI 10.1016/j.resp.2013.12.012
Rogerio AP, 2007, INFLAMM RES, V56, P402, DOI 10.1007/s00011-007-7005-6
Rogerio A.P., 2010, ANTIINFLAMMATORY EFF
Shiang C, 2009, CLIN EXP ALLERGY, V39, P1499, DOI 10.1111/j.1365-2222.2009.03281.x
Shichijo M, 2003, BIOL PHARM BULL, V26, P1685, DOI 10.1248/bpb.26.1685
SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201
Simoes S.M., 2005, REV BRAS ALERG IMUNO, V28, P2005
Spears M, 2006, CLIN EXP ALLERGY, V36, P1494, DOI 10.1111/j.1365-2222.2006.02604.x
Taguchi L, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0233-3
Takeda K, 2009, CURR OPIN IMMUNOL, V21, P660, DOI 10.1016/j.coi.2009.09.005
Teixeira MM, 1995, TRENDS PHARMACOL SCI, V16, P418
Toledo AC, 2013, BRIT J PHARMACOL, V168, P1736, DOI 10.1111/bph.12062
Velden J.V., 2012, EXP LUNG RES, V38, P307
Verdi LG, 2005, QUIM NOVA, V28, P85, DOI 10.1590/S0100-40422005000100017
WEIBEL ER, 1963, LAB INVEST, V12, P131
Wu YQ, 2006, LIFE SCI, V78, P2689, DOI 10.1016/j.lfs.2005.10.029
YANAI M, 1992, J APPL PHYSIOL, V72, P1016
Zanini A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-132
Zhou HF, 2011, J AGR FOOD CHEM, V59, P3060, DOI 10.1021/jf105017j

Coleções

Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo